- Home
- DH
as 12-20-2024 4:00pm EST
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. The company's solutions provide accurate and comprehensive information on healthcare providers and their activities to help customers optimize everything from product development to go-to-market planning and sales and marketing execution. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 518.7M | IPO Year: | 2021 |
| Target Price: | $6.15 | AVG Volume (30 days): | 518.0K |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.19 - $10.62 | Next Earning Date: | 11-07-2024 |
| Revenue: | $255,846,000 | Revenue Growth: | 3.97% |
| Revenue Growth (this year): | 2.58% | Revenue Growth (next year): | -3.71% |
Latest Definitive Healthcare Corp. News
DH Breaking Stock News: Dive into DH Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
DH vs. PRVA: Which Stock Is the Better Value Option?
Zacks
18 days ago
DH vs. PRVA: Which Stock Should Value Investors Buy Now?
Zacks
a month ago
Surging Earnings Estimates Signal Upside for Definitive Healthcare (DH) Stock
Zacks
a month ago
DH or PRVA: Which Is the Better Value Stock Right Now?
Simply Wall St.
a month ago
Definitive Healthcare Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St.
a month ago
Definitive Healthcare Corp. (NASDAQ:DH) Just Reported Earnings, And Analysts Cut Their Target Price
GuruFocus.com
a month ago
Definitive Healthcare Corp (DH) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
Zacks
a month ago
Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates
Compare DH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DH Definitive Healthcare Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.